DGX Stock: Quest Diagnostics Incorporated Stock Price, Analysis & Insights
Get live dgx stock price $177.41, comprehensive Quest Diagnostics Incorporated stock analysis, charts, news, and expert forecast. Real-time dgx stock data and investment insights.
Loading chart...
Company Overview
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Company Information
- CEO
- James E. Davis
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 55000
Contact Information
- Address
- 500 Plaza Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 20.8)
✓ Lower volatility stock (Beta: 0.62) may provide portfolio stability
Business Model & Strategy
Quest Diagnostics Incorporated operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO James E. Davis, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Quest Diagnostics Incorporated competes in the Medical - Diagnostics & Research within the broader Healthcare. With 19.8 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Quest Diagnostics Incorporated provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Quest Diagnostics Incorporated should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Quest Diagnostics Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Quest Diagnostics Incorporated
- ⚠Investors should consider how Quest Diagnostics Incorporated fits within their overall portfolio allocation
Market Cap
19.83B
P/E Ratio
20.80
Beta
0.62
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 19.83B market capitalization
- Trading Volume: 277.45K shares traded today
- Price Range: 52-week range of $148.70 - $197.55
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 19.83B, the company represents a significant player in its market. The stock is currently trading at $177.41 with a negativedaily change of 0.35%.
The company's 55000 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 20.80, beta of 0.62, and 52-week price range from $148.70 to $197.55when evaluating investment opportunities.
Why Invest in Quest Diagnostics Incorporated?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under James E. Davis
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.